NCT03653507 2026-04-17GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 3 FDA
NCT03157128 2026-04-16LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 24 charts 6 FDA
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA
NCT03915951 2026-03-24An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerPfizerPhase 2 Completed98 enrolled 18 charts 2 FDA